Amgen Goes Public With Kyprolis Value Data To Supplement ICER Review
This article was originally published in The Pink Sheet Daily
Executive Summary
In an unusually public discussion of drug value, the company releases its economic analysis for Kyprolis in advance of an ICER technology assessment of that drug and others for multiple myeloma. Amgen's Martin Zagari says manufacturers must find new ways to present alternative, "rigorous" points of view.
You may also be interested in...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.
Biden vs Trump On Drug Pricing And Unfinished Business
While more significant reforms are less likely under a second Biden term unless Democrats control both chambers of Congress, former President Trump could look to put his stamp on drug pricing reform by resurrecting one of his former policies involving international reference pricing and Medicare Part B drugs.